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Abstract
Sodium channel blockers are used to control electrical excitability in cells as a treatment for epileptic seizures and cardiac
arrhythmia, and to provide short term control of pain. Development of the next generation of drugs that can selectively
target one of the nine types of voltage-gated sodium channel expressed in the body requires a much better understanding
of how current channel blockers work. Here we make use of the recently determined crystal structure of the bacterial
voltage gated sodium channel NavAb in molecular dynamics simulations to elucidate the position at which the sodium
channel blocking drugs benzocaine and phenytoin bind to the protein as well as to understand how these drugs find their
way into resting channels. We show that both drugs have two likely binding sites in the pore characterised by nonspecific,
hydrophobic interactions: one just above the activation gate, and one at the entrance to the the lateral lipid filled
fenestrations. Three independent methods find the same sites and all suggest that binding to the activation gate is slightly
more favourable than at the fenestration. Both drugs are found to be able to pass through the fenestrations into the lipid
with only small energy barriers, suggesting that this can represent the long posited hydrophobic entrance route for neutral
drugs. Our simulations highlight the importance of a number of residues in directing drugs into and through the
fenestration, and in forming the drug binding sites.
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Introduction
Voltage-gated sodium channels (Navs) are transmembrane proteins
that initiate action potentials in excitable cells by responding to
small depolarizing signals to allow the rapid influx of Naz into the
cell [1–3]. Mutations and aberrant expression of sodium channels
are responsible for a range of diseases related to nerve and muscular
function including neuropathic pain, cardiac arrhythmia and
epilepsy [4,5]. These conditions often benefit from treatment with
drugs that block the passage of Naz and thereby rein in electrical
activity. In clinical settings, the local anesthetic activity of sodium
channel-blockers is also used to ease surgery or acute pain resulting
from trauma. While there are many molecules capable of blocking
sodium channels, most medically relevant drugs are small organic
molecules which bind inside the pore to impede ion flow by either
directly occluding the ion conduction pathway or by stabilizing a
non-conductive channel conformation [3]. The result is reduced
signal propagation, which manifests symptomatically as a reduction
in seizure occurrence, pain sensation or cardiac excitability.
Sodium channel inhibitors exhibit a wide range of chemical
moieties, but common to most of them is the presence of a phenyl
ring connected to a basic nitrogen, with some combination of
aromatic and aliphatic decorations [6,7]. Neutral local anesthetics
are known to be able to block and leave resting sodium channels
when applied from either side of the membrane, a process known
as ‘tonic block’. In contrast highly polar or charged compounds can
only block the pore after channel opening yielding ‘use dependent’
block that is the basis of anti-epileptic or anti-arrhythmic activity
[8,9]. The observation of multiple modes of drug block led to the
suggestion that there are two access routes for drugs to enter the
channel: through the activation gate from the cytosol or directly
from the lipid bilayer through a ‘hydrophobic route’ [8].
Humans have nine different types of voltage-gated sodium
channels, which are preferentially expressed in different tissue [2].
Most sodium channel blocking drugs target all subtypes, but the
development of selective channel blockers would allow a new
range of clinical applications and a decrease in side effects [7]. For
example, there is significant interest in increasing the specificity of
drugs for the channel subtypes found in pain receptor neurons as a
way to combat chronic pain [10,11]. However, developing subtype-
selective Nav channel blockers requires the generation of in-depth
knowledge of the location of binding and the route of entry of
existing drugs in order to assess how small sequence differences in
the subtypes can be exploited. The presence of a common chemical
moiety in sodium channel inhibitors also raises the question of
how drugs with similar structure and binding sites, such as local
anesthetics and anticonvulsants, have differing therapeutic effects
[12]. A better understanding of the specific interactions of these
compounds with residues in the channel and their access route may
suggest strategies for altering drug kinetics and affinities.
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While there are no atomic resolution structures of eukaryotic
voltage gated sodium channels (eNavs), the recent publication of a
number of structures of homologous channels from bacteria
(bNavs) [13–17] provides an avenue to understanding how sodium
channel blockers work at the molecular level. The first crystal
structure of a bNav from Arcobactor Butzleri, called NavAb, shows
the protein is a tetramer of four identical subunits, with the pore
axis running down the central axis [13]. Each subunit contains a
pore forming domain consisting of two transmembrane helices (S5
and S6) joined by a linker that forms the narrow selectivity filter at
the extracellular end of the pore. Beneath this is a central, water-
filled cavity, walled by the S6 helices, where most channel-block-
ing drugs are known to bind in eNavs [18–22]. The pore tapers at
the intracellular end to form the activation gate which is closed in
this structure so that drugs cannot pass from the cytosol into the
central cavity. Recent electrophysiological studies have shown that
the local anesthetics lidocaine, ranozaline and benzocaine can
block sodium flux in NaChBac, the most well characterised bNav,
with comparable affinity to tonic block in eukaryotic channels
[9,23]. Supporting the similarity between the bacterial and eukary-
otic channels, uncharged drugs such as benzocaine can block
NaChBac when applied extracellularly indicating that the hydro-
phobic route for drug entry is still present [9]. The published bNav
structures present a candidate for this drug access route as they show
lateral fenestrations extending to the membrane from the center of
the pore, which are large enough to fit small molecules [24,25], and
through which the general anesthetic isoflurane has been seen to
pass in simulation studies of a NachBac homology model [26].
Despite the similarities between bacterial and eukaryotic voltage
gated sodium channels that may make bNavs good models for
studying tonic block, there are also functional and structural dif-
ferences. NaChBac exhibits far slower gating kinetics than eNavs
[27], precluding the study of use-dependent block in which recovery
from inactivation must occur faster than drug dissociation. Struc-
turally, bNavs are composed of four identical subunits, whereas
eNavs are a single, heterotetrameric protein chain [27,13]. Although
there is common hydrophobic character in the pore, sequence
alignments show that residues forming the putative drug receptor
site on the internal S6 helix are not conserved between bacterial and
eukaryotic Navs [28], and specifically NavAb lacks aromatic
residues near the drug binding site that are suspected to be
particularly important in use-dependent binding [21].
In order to better understand the mode of action of sodium
channel inhibitors, here we use molecular dynamics simulations to
examine the route of entry and mechanism of binding in NavAb of
two channel-blocking drugs: the local anesthetic benzocaine, and
the anti-epileptic phenytoin. Both are small, neutral drugs that
bind inside the pore of eNavs [29,20] and whose blocking effect
tapers off after some time [30,31], indicating they may leave the
channel via the observed hydrophobic fenestrations. Benzocaine
has been shown to illicit tonic block of NachBac [9]. Equilibrium
and biased simulations are used to identify the potential binding
sites of these two drugs in the pore, and to quantify the affinity of
binding. Accompanying this is a demonstration of drug passage
through the hydrophobic fenestration, showing that this pathway
is a feasible route of access or escape for neutral channel-blocking
drugs.
Results
Locating potential drug binding sites
As described above, mutation studies strongly support the
notion that local anesthetics bind to residues in the central cavity.
For this reason we limit our search for possible binding sites to the
channel cavity and fenestrations in order to more extensively
sample potential binding pockets (meaning that we will not pick up
any sites on the exterior of the protein.) To gain a first appreciation
of where the drugs might interact with the protein and to observe
drug behaviour inside NavAb, we start our investigation by
placing phenytoin or benzocaine in the middle of the central cavity
of both the closed and inactivated conformations and allow them
to explore the interior of the pore without external influence.
Although the size of the cavity is small and the drugs rapidly move
about in this region, the timescale of our simulations is shorter
than the typical time taken for drugs to block the channel, so it is
possible that the drugs will not find their way to the most likely site
in the pore. However, this approach does enable us to make a first
identification of potential binding pockets which can be verified
with the more exhaustive metadynamics search described below.
As will be described later, the same binding positions found in
these equilibrium simulations are found in two additional indepen-
dent methods, lending support to them representing likely binding
positions in the bacterial channel NavAb.
Fig. 1 illustrates the results of a cluster analysis performed on 3
independent 125 ns simulations starting from different initial drug
orientations for each protein/drug combination. The snapshots
shown highlight the most commonly occupied locations of the
drug in the pore. Both phenytoin and benzocaine explored widely
throughout the cavity in the repeated simulations, sampling the
majority of one of the four homologous cavity walls, and both
drugs experienced stable and enduring association to two sites in
the channel cavity. In each of our simulations the drug spends the
majority of the time in one of the positions highlighted in Fig. 1,
indicating that the timescale to move between stable positions is
relatively long and that a single simulation will have difficulty to
sample all possible positions. However, we do see a number of
events in which drugs move between sites or reorient within a site
suggesting that amongst our 12 simulations we are likely to be
finding the most stable positions in the pore.
One of the most commonly occupied sites is formed by the hydro-
phobic pocket above the intracellular activation gate, created by the
confluence of the four S6 segments at the pore axis (location shown
in green in Fig. 1). The second most common site was in one of the
four hydrophobic fenestrations that exist between the protein
subunits (blue in Fig. 1). Phenytoin, the bulkier molecule, sampled
less deeply into the hydrophobic pockets. In contrast benzocaine
extends further into the pockets, and in one case even traveled
through the fenestration to bind on the outside of the protein. This
event, in which the benzocaine moved outward from the position
shown in blue in Fig. 1C (green), is notable in that it demonstrates
the possibility of leakage of local anesthetics from an otherwise
blocked channel.
Author Summary
The treatment of cardiac arrhythmia, epilepsy and pain
usually involves blocking the protein channels responsible
for initiating electrical activity in nerves and muscles.
Current drugs block all such channels, but improved
medication requires compounds that can differentiate
between the channels present in different parts of the
body. Achieving this goal calls for a better understanding
of the interactions of current drugs with the proteins. Here
we use computer simulation to understand where a local
anesthetic and an anti-epileptic bind to a bacterial sodium
channel and how they find their way to this position,
helping to uncover ways to selectively target different
human channels.
Entry Route and Binding Sites of Local Anesthetics in a Sodium Channel
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Confirming the binding locations with metadynamics
Although similar binding positions are seen in each of the 12
independent equilibrium simulations, it is possible that the drugs
do not sample all potential sites in the pore. To ensure that we
have not missed any important binding site in the equilibrium
simulations, metadynamics simulations were run to force the drugs
to move throughout the entirety of the pore, providing a much
more exhaustive search of the cavity and fenestrations. By adding
a wall to prevent the drug moving beyond the external end of the
fenestrations selectivity filter or activation gate, the pore forms an
enclosed space meaning that the method can also be used to
obtain the relative free energy of each position in the pore. The
free energy surface for benzocaine (Fig. 2) shows two minima,
which correspond to the binding sites observed in the unbiased
simulations. Binding at the activation gate is found to be slightly
more favourable (by ,3 kcal/mol) than at the entrance of the
fenestration. This surface also indicates the relative ease with
which benzocaine can pass through the fenestration, with barriers
of only a couple of kcal/mol to move out from the fenestration
binding site to the outside of the protein. Phenytoin shows one
clear minimum in the activation gate with a second small
minimum present near the hydrophobic fenestration. Remarkably,
both drugs experience relatively low barriers to push through the
closed activation gate (see barriers at the bottom of Fig. 2. B&D),
although the absence of the C-terminal domain in the simulations
may be aiding this. It can be seen from the range of of x, y and z
coordinates represented in the free energy surfaces (Fig. 2) that the
drug moves through all possible positions in the cavity and
fenestrations. In Fig. S1 we plot the drug orientation as a function
of time, which shows that both drugs sample all possible orienta-
tions. The exhaustive search undertaken with the metadynamics
simulations confirms the binding poses found in the equilibrium
simulations and indicate that for both drugs, binding in the NavAb
activation gate is stronger than in the fenestrations.
Characterising the drug binding sites
Representative snapshots of each of the identified binding sites
(taken from the cluster analysis) are shown in Fig. 3 and Fig. S2. In
each potential binding site, non-polar moieties of the drug extend
into the hydrophobic pockets of the channel cavity. While it is
most common to find the polar amine of each drug solvated by
water in the central channel cavity, benzocaine can sit in either
orientation in the activation gate or fenestration as shown in Fig. 3
A–C. Phenytoin, on the other hand, always buries one of the
phenyl rings deep into a hydrophobic pocket. To further charac-
terise the sites, the interaction energy was determined between
each drug and each protein residue (Fig. 4). As can be seen in both
Figs. 3 and 4, binding in the activation gate is primarily composed
of interaction with residues M209, I210, V213 and I217. Binding
in the hydrophobic fenestration is primarily composed of interac-
tions with S6 residues T206 and M209 and P2 residues M174, T175
and L176, as well as residues M137 & T138 for benzocaine which
Figure 1. Drug positions in unbiased simulations. 20 Equally spaced snapshots from three unbiased simulations of benzocaine (A and C) and
phenytoin (B and D) in the closed (A and B) and inactivated (C and D) NavAb. Each colour represents snapshots from a different simulation, while a
single protein conformation is shown in each case.
doi:10.1371/journal.pcbi.1003688.g001
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can penetrate deeper into the pocket. It is also evident that van der
Waals interactions are more significant than electrostatic forces
(Fig. S3).
Since both drugs are uncharged and there are no aromatic
residues available for pi-pi stacking or cation-pi interaction in the
NavAb channel lumen, nonspecific binding based on van der
Waals attraction to hydrophobic pockets seems to be the dominant
force behind drug association in our simulations. Both the identified
binding sites involve significant interactions with residues at
positions previously shown to be important for block in eukaryotic
channels [19], however this appears to be due to their location and
hydrophobicity, rather than any specific chemical moieties that
interact with benzocaine or phenytoin. Our results are consistent
with previous studies that suggest that the local anesthetic site for
tonic block is spread out over several residues and is hydrophobic in
nature [32]. Despite the positions of binding being consistent with
expectations from studies of eukaryotic channels, it is difficult to use
the present results to directly rationalise the mechanisms of block in
the eukaryotic case. There is a significant sequence difference
between bacterial and eukaryotic channels in the central cavity,
notably a lack of aromatic residues, as well as the bacterial channels
being homotetramers. The lack of specific interactions found here
contrasts with the large affinity differences obtained for phenytoin
derivatives (containing different aromatic rings and substituents) in
Nav1.7 [33], presenting a further warning that the mode of bind-
ing in bacterial channels may differ from that in the eukaryotic
Figure 2. Free energy surfaces for (A,C) benzocaine and (B,D) phenytoin in the NavAb central cavity viewed along the pore axis
(A,C) and from the membrane (B,D) obtained from metadynamics simulations. Contours are shown at 1 kcal/mol intervals.
doi:10.1371/journal.pcbi.1003688.g002
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Figure 3. Snapshots of the most commonly sampled binding poses. The drug and surrounding residues are shown. The residues with the
strongest interactions with the drug are named in bold. (A) benzocaine in the activation gate with amine pointing at the central cavity. (B)
benzocaine in the activation gate with amine pointing down. (C) benzocaine in a fenestration with amine pointing to the central cavity. (D)
Benzocaine in a fenestration with amine pointing toward the lipid. (E) Phenytoin in the activation gate. (F) Phenytoin in a fenestration.
doi:10.1371/journal.pcbi.1003688.g003
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counterparts due to the different composition of the pore lining
residues. Most experimental studies examine drug binding of the
inactivated state, as this is in general stronger than that found for
closed channels. The bacterial channels may represent a better
model of tonic block to closed channels than inactivated channels as
there is evidence this is not based upon aromatic association [32].
We hope that the interactions described here for NavAb can be
experimentally tested via mutagenesis in the future.
Drug binding affinities
To assess the strength of binding relative to bulk in each of the
two sites identified in the unbiased and metadynamics simulations
we employed the method of free energy perturbation. Using this,
the binding free energy of each drug in each site was determined,
from which the dissociation constant was calculated for comparison
to experimental measurements. As shown in Table 1, phenytoin and
benzocaine have comparable affinity for the NavAb activation gate.
For both phenytoin and benzocaine binding in the activation gate
was stronger than binding in the hydrophobic fenestration, as seen
in the metadynamics simulations.
For benzocaine, published values for the dissociation constant in
closed eukaryotic channels range from 0.3–1.2 mM [34–36] and a
similar value (0.65 mM) is seen for NaChBac [9]. Benzocaine is
known to bind within the central pore [19], and the current
understanding of neutral drug-binding to the closed state supposes
that binding is caused by hydrophobic interactions to a diffuse
receptor spreading across several residues [32]. The dissocia-
tion constant relative to bulk water in our simulations is in the
5 – 100 mM range. While this does suggest stronger binding in the
simulation, a direct comparison with experiment is complicated by
a number of factors. Firstly, both benzocaine and phenytoin are
seen to strongly partition into lipid bilayers [37] which can
influence observed and simulation dissociation rates. Secondly,
since it will not be present in open channels, the activation gate site
will only be relevant if drug binding here can alter the open
probability of the channel, something which is difficult to assess.
Finally, binding of a single drug in the fenestration does not fully
occlude the pore meaning that the binding of another drug to
another subunit (likely at lower affinity) may be necessary to block
the passage of Naz. However, the similarity in the dissociation
constants in the bacterial and eukaryotic Navs, and the consistency
of the binding poses seen in our simulation with mutagenesis data,
add support for NavAb representing a good model for tonic block
of eukaryotic sodium channels by benzocaine. However, we note
that since use-dependent block probably relies on an increase in
affinity to the open/inactivated states [35,36] facilitated by
aromatic residues that are not conserved in NavAb [21], this
channel is less likely to form a good model of use-dependent block.
Experimental dissociation constants for phenytoin binding to
the closed channel are rare, due to its low solubility and affinity to
this state. In eukaryotic channels, phenytoin has been shown to
bind to inactivated channels with a dissociation constant in the
range of 4 – 9 mM, with affinity up to 100-fold weaker in the closed
state [31,38,39]. This provides similar agreement to our current
result as for benzocaine. While there is some evidence for
phenytoin binding on the external surface of the protein rather
than in the pore [40] mutations to the internal local anesthetic
binding site have shown these residues to be the major
determinants of binding [20]. Our results suggest that if phenytoin
does bind internally, NavAb may be a also be a reasonable model
for closed-state binding of phenytoin.
Drug entry through hydrophobic fenestrations
Drug passage through a hydrophobic pathway has long been
hypothesized in sodium channels [8]. The bNav crystal structures
all exhibit small fenestrations between homologous domains,
which are potential routes for drugs to move into or out of closed
or inactivated channels [13–17]. Previous molecular dynamics
simulations in the absence of drugs have shown that the size if the
fenestrations is likely to be sufficient to allow the passage of a small
molecule such as benzocaine [24,25]. Simulations with a drug
present have the ability to directly assess the feasibility of drugs
Figure 4. Drug-protein interactions in each site. The interaction
energies for (A) benzocaine and (B) phenytoin with residues lining the
channel lumen when the drug is in one of the commonly occupied
clusters. Four significantly different cluster are shown for benzocaine,
corresponding to those pictured in Fig. 1 & 3. Two clusters are shown
for phenytoin corresponding to binding at the activation gate (green)
and fenestration (blue). Residues from regions not having significant
interactions with the drugs are omitted.
doi:10.1371/journal.pcbi.1003688.g004
Table 1. Free energy of binding, and dissociation constants
relative to bulk water for phenytoin and benzocaine at two
sites in the NavAb central cavity.
DGbind (kcal=mol) Kd (mM)
Benzocaine Activation gate {7:2+0:4 5:2+2
Fenestration {5:6+1:0 78+30
Phenytoin Activation gate {8:2+0:2 1:0+0:3
Fenestration {6:1+0:1 30+10
doi:10.1371/journal.pcbi.1003688.t001
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passing through these fenestrations and to examine the energetics
and steps in the process. As noted above, benzocaine passes
through a fenestration and binds on the outside surface of NavAb
in one of our 125 ns equilibrium simulations, giving direct evidence
that this molecule can move out of the channel via the fenestration.
To determine the forces involved in such motion we used umbrella
sampling to construct free energy profiles (potential of mean force,
PMF) for the process.
As shown in Fig. 5, moving from the lipid bilayer into the
central cavity is associated with a net negative change in free
energy for both drugs. Both drugs show multiple minima inside the
central cavity: at the activation gate (0 A˚) and at the entrance to
the fenestration (,5,10 A˚) in agreement with the equilibrium and
metadynamics experiments. The site by the activation gate is
about 2 kcal/mol more stable than that by the fenestration,
reinforcing the results seen in our earlier calculations. Furthermore
the barriers between the sites are in close agreement with what is
seen in the metadynamics profiles. Comparatively, phenytoin
shows a greater free energy change upon binding in the channel
from the lipid than benzocaine, supporting the stronger binding
affinity found here and in the literature. Previously we have shown
that both drugs will partition into the bilayer from bulk water with
a free energy change of 24.6 and 23.0 kcal/mol for benzocaine
and phenytoin respectively [37]. Combining this with the free
energy change for each drug to enter the channel from lipid seen
in Fig. 5 yields a total binding free energy in close agreement
(within 1 kcal/mol) with that found from the free energy
perturbation calculation (table 1). While it may be feasible for
phenytoin to enter through the fenestration, it faces larger barriers
and will have a harder time leaving the pore via this route than
does benzocaine.
Movement of benzocaine and phenytoin through the fenestra-
tion is associated with extension of water chains from the channel
lumen into the fenestration and possible retraction of resident lipid
tails. Without the drug present, lipids extend into each fenestration
for the majority of our simulations (eg Fig. 6A) as suspected from
the crystal structure [13]. Benzocaine can move past the resident
lipid tails without significantly displacing them as shown in Fig. 6B.
However, the bulkier phenytoin cannot fit in the mid part of the
fenestration with the lipid tails, and these have to move out of the
way as the drug passes, similar to what is seen for isoflurane [26].
Examples in which the drug and lipid co-exist in the fenestration
are shown in Fig. S4. Passage of the drugs through the inner part
of the fenestration is also stabilised by a single-file water chain that
extends from the channel lumen to contact polar moieties on the
drug. This water chain tends to form up to the point that the drug
passes the bulky F203 residue as seen in Fig. 6D, but remarkably,
at times this chain extends the entire length of the fenestration
when the drug resides on the outside surface of the protein
(Fig. 6C). As seen in Fig. 6D the water chain tends to extend
further to the more polar phenytoin than it does to benzocaine,
similar to what is seen in simulations of the partitioning of these
drugs into lipid bilayers [37].
Fig. 7 shows representative snapshots of the system at points
corresponding to minima on the PMF. Two minima identified in
the equilibrium simulations and metadynamics are reproduced
here - namely in the activation gate (0 A˚) and in the fenestration
(11 A˚). The bulky phenylalanine that constricts the fenestration
(F203) appears to hinder the passage of both drugs as seen by the
barriers in the region 15 A˚–18 A˚, but also contributes to pi-pi
stacking with the aromatic moieties. Once on the outside surface of
the protein, both drugs exhibit enduring association with F203 (pi-
pi stacking) as well as with T138 (yellow in Fig. 6), the one polar
residue near the mouth of the fenestration to which it can
hydrogen bond.
Moving from the bulk lipid into the fenestration requires the
drugs to move into the hydrophobic core of the membrane,
something previously shown to be unfavourable [37]. Benzocaine
is seen to slide slowly down the side of the protein from its
preferred position near the lipid headgroups toward the mouth of
the fenestrations. Because of this it only makes significant contact
with water molecules from bulk when far from the protein (Fig. 6D
dashed line). The interaction of benzocaine with the protein helps
to reduce the energetic barrier for penetrating deep into the
bilayer. In contrast, phenytoin has greater difficulty in penetrating
into the centre of the bilayer as seen by the bump in the free
Figure 5. Potentials of mean force for benzocaine (red) and phenytoin (blue) moving from the pore axis (0 A˚) to the lipid (w24 A)
through one of the hydrophobic fenestration (10–20 A˚). Snapshots of the drugs at positions along the fenestration are shown in Fig. 7.
doi:10.1371/journal.pcbi.1003688.g005
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energy profiles at around 21 A˚. This corresponds to a sudden
move from the lipid headgroups to the mouth of the fenestration
and the rapid breakage of the water chain to the bulk water
(Fig. 6D dashed line). Dehydration of the drug as it enters the
bilayer is the principle cause of this barrier. While the hieght of the
barrier is significant (,5 kcal/mol), it is not as large as in the
absence of protein [37].
Accurately converging the right hand side of the free energy
profiles is difficult. Once the drug leaves the fenestration it can
sample more positions at the given coordinate value and there are
a number of slow motions that are hard to sample in the 30 ns of
simulation we allow for each drug position. These slow motions
include lipids entering/leaving the fenestrations, the drug moving
between leaflets of the bilayer and the formation and breakage of
water chains. Although the PMF does not change significantly when
we extend our simulations (Fig. S5) we have noted a dependence
upon the starting coordinates used in each window. Given the
difficulty in sampling this region and the long timescale of some of
the important motions, some care should be taken in reading
quantitative values from the free energy profiles. However, the close
agreement of our PMF to the metadynamics and FEP experiments,
particularly in the interior of the channel and fenestration, provides
confidence that this area is well sampled.
Discussion
Using molecular dynamics simulations we have characterised
the likely binding sites for benzocaine and phenytoin inside the
central cavity of NavAb, with 3 independent simulation methods
yielding consistent results. Both drugs are found to bind either in
the hydrophobic pocket formed by the activation gate or at the
entrance to the hydrophobic fenestrations. In both cases, the drugs
Figure 6. Lipid and water in the fenestrations as a function of drug position. (A) A representative snapshot showing lipid occupying the
lateral fenestrations while benzocaine sits at its minimum energy position in the activation gate. The position of F203 (orange) and T138 (yellow
surface) are also shown. (B) The extent to which lipid penetrates into the fenestration is plotted as a function of the position of each drug. Low values
indicate extension further into the fenestration. (C) A snapshot showing an extreme example of a water chain extending from the channel lumen to
phenytoin on the exterior surface of the protein. In most cases the water chain does not extend this far. (D) The probability that a continuous water
chain extends from each drug back to the channel lumen as a function of drug position (solid lines). Also shown is the probability that a water chain
extends from the drug directly to bulk water (dashed lines). In B and D the data for individual windows are shown in points and a moving average of
5 data points is indicated by the line.
doi:10.1371/journal.pcbi.1003688.g006
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interact with residues found to be important in binding in eNavs.
But, we find this association is due to non-specific hydrophobic
interactions meaning that binding occurs due to the overall
architecture of the central cavity rather than interactions to
specific residues. Although our simulations clearly identify the
likely drug binding sites in the channel, it is not yet clear if the
binding of more than one drug is necessary to occlude the pore or
prevent channel opening. Our simulations also provide a plausible
rationalisation for the differences seen between tonic and use
dependent block, as interaction of cationic drugs with aromatic
residues are essential in the use dependent case but not for resting
state block [21,32]. It is possible that the most likely binding
position in the resting channel could be at the activation gate as
found here, but this will be abolished upon channel activation
allowing the drug to move close to the aromatic residues present in
eNavs. If this hypothesis is correct, mutation of residues involved
only in binding at the activation gate would be expected to change
the affinity of tonic block, but not use-dependent block. Unfortu-
nately, the lack of aromatic residues in the pore and the slow
channel kinetics seen for NaChBac make these channels less ideal
for modelling use-dependent block in either simulation or exper-
iment - but they still may allow for modeling of eukaryotic tonic
block. We note that the dissociation constant for tonic block by
benzocaine in eukaryotic channels [41] closely matches that for
bacterial channels [9].
Our results also show that the hydrophobic fenestrations seen in
NavAb can serve as conduits for benzocaine and phenytoin to
enter the central cavity and thus can form the long hypothesised
hydrophobic entrance route [8]. There are three lines of evidence
supporting this conclusion: (i) benzocaine exits through a fenestra-
tion during one of the equilibrium simulations, (ii) the energy
barriers to reach the outside of the protein are small as found from
metadynamics simulations, and (iii) the PMF plots indicate small
barriers for drug entry, although larger barriers are present for
penytoin than for benzocaine. The main barriers to passage
through the fenestration appear to be physical constrictions in the
fenestrations which is consistent with experiments in eukaryotic
channels, in which analogs of benzocaine show slower rates of
dissociation from sodium channels when they have bulkier or
longer moieties attached [42]. It has been suggested that there may
be scope to exploit any differences in the size of the fenestrations in
different eNav subtypes or in different functional states to rationally
design sub-type or state dependent channel blocker [16,14],
however, our previous simulation have suggested there is little state
dependent difference in fenestration size [24]. In addition the
concept of drug entry through the fenestration may be further tested
using mutations in this area. Surprisingly, the potential entropic
issues associated with the drug finding the small fenestration entrance
appear to be small. The fact that lipids are seen to exchange in long
simulations, that they are replaced by drug and water, and that
polar residues on the surface of the protein can attract drugs from
the bilayer may all help to overcome this potential barrier. Polar
residue in this region (T138,Y142) are well conserved in bNavs and
it would be interesting to see if their mutation altered the kinetics of
drug entry.
The large degree of sequence similarity in the pore forming
regions of eNavs makes the design of subtype selective channel
blockers a difficult goal. Elucidating the mode of entry and binding
of existing channel blockers is an important step toward achieving
this aim. Here we have been able to do this for benzocaine and
phenytoin in a bacterial channel, but it is not clear how much
about binding in eukaryotic channels can be inferred from this
given the significant differences between these families of proteins.
For example, the nature of binding seen here is likely to be less
Figure 7. Snapshots from the umbrella simulations are shown that
represent important points in the PMF for benzocaine (A–D) and
phenytoin (E–H). The global minimum for each drug is at the activation
gate (A,E), and the drug positions here replicate the binding poses seen in
the equilibrium simulations. The same is true for the secondminimum (B, F),
which shows binding in the fenestration. A further hydrophobic pocket
supports the drugs in the outer fenestration (C,G). At the external entrance
to the fenestrations, the drugs have to pass the bulky phenylalanine residue
(orange) and are at their most dehydrated creating the largest barrier in the
pathway (D,H). Example snapshots show that even at this point water
chains extending to the channel lumen are sometimes present.
doi:10.1371/journal.pcbi.1003688.g007
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specific than that in the eukaryotic homologues. Additional
functional studies of drug block in bacterial channels, increased
availability of structural information about the different functional
states of bacterial channels, reliable models of eukaryotic channels
and detailed investigations of specific drug-residue interactions in
tonic and use-dependent block will all aid progress toward the
design of subtype selective channel blockers.
Methods
Simulation systems
Two simulation systems were set up based on the NavAb sodium
channel with coordinates obtained from the protein database: a
closed/pre-open channel; PDB accession code 3RVY [13] and a
potentially inactivated channel; PDB accession code 4EKW [14].
The voltage sensors (residue numbers below 115) were removed
from both systems to reduce the system size and computational load,
as experimental studies have shown this still yields a functional
channel in other bNavs [43,44]. Each system was placed in a pre-
equilibrated POPC lipid bilayer, and solvated in a 72672682 A˚
box of TIP3P water with 250 mM NaCl. A picture of one such
system is given in Fig. S6. The systems were equilibrated as for our
previous simulations [45]: the protein was first held fixed while
water and lipid were allowed to equilibrate for 2 ns. Then the
protein alpha carbons were then restrained by a harmonic potential
with force constant reducing from 10 kcal/mol to 0.1 kcal/mol in 4
steps over 10 ns. To get lipid to rapidly take up position in the
fenestrations as indicated in the crystal structure, four lipid tails were
restrained in the fenestration during the equilibration period, but
this restraint was removed in subsequent simulations and lipids
remained present in the fenestrations for the duration of the equilib-
rium simulations. All simulations were run with periodic boundary
conditions with constant pressure of 1 atm and temperature 298 K
maintained using a Langevin Piston and Langevin dynamics
respectively. The CHARMM 27 force field was used for proteins
[46] and CHARMM36 lipid [47] and ion parameters were taken
from Joung and Cheatham [48]. A 2 fs timestep was used with all
bonds to hydrogen atoms fixed. Parameters for benzocaine and
phenytoin were chosen from those best replicating water/octanol
partition data as described in our previous work [37].
Equilibrium simulations
In order to gain a first idea of the likely position of drug binding
in the central pore cavity, three simulations lasting 125 ns each
were run for each protein/drug system (yielding a total of 12
simulations). In each of these the drug was placed in the center of
the cavity with a different random orientation. Once complete, the
first 25 ns was excluded from further analysis to allow for equili-
bration of the drug in the channel, and the three trajectories for
each protein/drug system were combined. Cluster analysis was
performed on the drug position in the combined trajectory (after
aligning the protein coordinates) using the quality threshold
algorithm to locate the most commonly occupied drug positions.
For this purpose we clustered according to RMSD of the drug
coordinates using a cutoff of 3 A˚. To determine which residues the
drug interacts with in potential binding sites, the NAMDEnergy
plugin was used to measure the interaction between the drug and
chosen residues for selected subsets of the trajectory corresponding
to each cluster.
Metadynamics
To better assess if the equilibrium simulations had sampled the
most likely drug binding poses, metadynamics [49,50] was utilised
to force the drugs to sample the entire pore. For this purpose, a
metadynamics bias was applied to three collective variables, which
described the x, y, and z coordinates of the drug centre of mass
inside the central cavity. A restraint was applied to the backbone
atoms of the NavAb residues on the S5 helices, with a spring
constant of 0.2 kcal/mol. This allowed Cartesian coordinates to be
used for the metadynamics collective variables. Well tempered
metadynamics [51] with a bias-factor of 10 was applied using the
PLUMED package [52]. To improve sampling, boundaries were
imposed using flat bottomed harmonic potentials to prevent the
drug from passing out of the fenestrations or beyond the activation
gate. Boundaries were also employed to focus sampling on a single
quarter of the x,y plane making use of the inherent four fold
symmetry of the protein. Gaussians with a height and width of
0.25 kcal/mol were deposited every 1000 timesteps, equivalent to
2 ps. Results represent 400 ns of simulation for each drug.
Free energy perturbation
Free energy perturbation [53] was used to calculate the free
energy difference between a solvated and a bound drug. The
perturbation experiment was performed in the forward (solvated
to bound) and reverse (bound to solvated) directions to assess
reproducibility of the calculations. In addition two independent
sets of simulations were made, one in which the solvated drug
appeared in the bulk water region of the same protein simulation,
and one in which the solvation energy of the drug was determined
in a completely separate simulation of a water and ion containing
box, and the quoted results represent the average of all the
simulations. These calculations used the native alchemical free
energy module present in the NAMD software in only closed the
NavAb. The transformation was stratified into 40 l windows,
differing by 0.025. For each window, 0.5 ns of equilibration was
performed, before ensemble averaging was turned on for 2 ns. A
softcore potential [54] was used to avoid explosively large energy
values at each end of the l scale when one of the drugs was nearly
annihilated. This scaled down the electrostatic interactions from
l~0:5 to l~1, and the van der Waals interactions from l~0 to
l~1 for annihilated particles. During free energy perturbation,
the free energy wells that define binding sites are flattened as a
drug disappears and particle interactions are scaled down, so
positional restraints were applied to bound drugs to ensure they
remain in the relevant region of the protein. A flat bottomed 2 A˚
radius harmonic potential with 5 kcal/mol spring constant was
applied to keep the drug centre of mass close to the centre of mass
of a set of residues determined in the equilibrium simulations.
Each restraint enclosed the drug in a sphere of radius 2 A˚ using a
harmonic potential with a 5 kcal/mol spring constant. To achieve
complete sampling in bulk an identical restraint held the solvated
drugs to a dummy atom in water, and the energy values were
corrected for the associated loss in translational entropy.
The equilibrium constant of the drug binding to each site were
calculated using the following relation [55]:
Kb~exp({DG=KT) ð1Þ
where Kb is the binding affinity, K is the Boltzmann constant, T is
the absolute temperature and DG is the free energy change for the
drug to enter the binding site from bulk water as found in the free
energy perturbation simulation. The dissociation constant Kd was
calculated using the relation Kd~1=Kb.
Umbrella sampling
The energy profile for drugs to pass through the lateral fenestrations
from the channel cavity into the lipid bilayer was determined using
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umbrella sampling [56]. Starting coordinates for these simulations
were generated in two ways. In the first, steered molecular dynamics
was used to pull the drug centre of mass through the fenestration
and into the lipid at a rate of 2 A˚/ns, from which coordinates were
saved at 2 A˚ intervals. In the second, the drug was equilibrated in
bulk lipid and starting coordinates were generated by pulling the
drug back into the fenestration. In both cases the drug position was
defined from the distance from a plane passing through the pore
axis perpendicular to the direction of the fenestration (equivalent to
the x-coordinate of the drug center of mass in our simulation
system). The position of the centre of mass of the drug was then
restrained in 0.5 A˚ intervals along the fenestration using PLUMED
[52] to create a harmonic potential with force constant 3 kcal/mol.
Additional restraining walls were put in place using a harmonic
external potential with a spring constant of 10 kcal/mol to focus
sampling on a 20 A˚-wide portion of the lipid bilayer (defined by the
y-coordinate of the drug center of mass). Each window was run for
30 ns of simulation, with the first 5 ns used as equilibration.
Simulations using the first set of stating coordinates were used for
the left hand part of the profile (x # 16 A˚), while those with the
second set of starting coordinates for the right hand part of the
profile (x $ 12 A˚), with both data sets used for the overlapping
region. This yielded a total of 2:5 ms of simulation per drug. Three
additional windows with a force constant of 10 kcal/mol, were
required for phenytoin to ensure good overlap between the windows
midway through the hydrophobic fenestration. Collective analysis
of the data was made using the Weighted Histogram Analysis
Method [57,58], using the implementation of Grossfield [59], to
produce a one dimensional potential of mean force. Uncertainties
were estimated from the standard error in the mean found when
dividing the data into 3 blocks and convergence of the profiles is
discussed in the supplementary material.
Supporting Information
Figure S1 Orientations of the drugs as a function of
time during the metadynamics simulations.
(PDF)
Figure S2 Representative snapshots of the binding
poses of benzocaine phenytoin.
(PDF)
Figure S3 Drug-protein interaction energy decomposi-
tion. The interaction energies for benzocaine and phenytoin and
residues in NavAb are decomposed into van der Waals and
electrostatic components.
(PDF)
Figure S4 Snapshots from umbrella simulations. These
show benzocaine and phenytoin occupying a hydrophobic
fenestration at the same time as a lipid molecule from the bilayer.
(PDF)
Figure S5 Convergence of the potentials of mean force
(PMF).
(PDF)
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